Llovet, Patricia <br/><br/>
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.  [electronic resource] 

 -  Molecular diagnosis & therapy  Dec 2015 
 - 397-408 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-2000 
<br/><br/><label>Standard No.: </label>10.1007/s40291-015-0165-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amphiregulin<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Class I Phosphatidylinositol 3-Kinases<br/>Codon<br/>Colorectal Neoplasms--drug therapy<br/>DNA Copy Number Variations<br/>DNA Mutational Analysis<br/>Disease-Free Survival<br/>EGF Family of Proteins--genetics<br/>Epiregulin--genetics<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gene Dosage<br/>Gene Expression<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Mutation, Missense<br/>Neoplasm Metastasis<br/>PTEN Phosphohydrolase--genetics<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Prognosis<br/>Proportional Hazards Models<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>ROC Curve<br/>Retrospective Studies<br/>Treatment Outcome